Acorda  (ACOR - Get Report) shares shot up Thursday afternoon, climbing 7%, after a judge ruled that a patent challenge brought by hedge fund manager Kyle Bass was invalid. 

Bass brought four patent challenges against the company's Ampyra drug, but the judge ruled against all four challenges.